- Home
- FOXO vs BGLC Comparison
FOXO vs BGLC Comparison
Compare FOXO & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXO
- BGLC
- Stock Information
- Founded
- FOXO 2019
- BGLC 2017
- Country
- FOXO United States
- BGLC Malaysia
- Employees
- FOXO N/A
- BGLC N/A
- Industry
- FOXO Retail: Computer Software & Peripheral Equipment
- BGLC Medical Specialities
- Sector
- FOXO Technology
- BGLC Health Care
- Exchange
- FOXO Nasdaq
- BGLC Nasdaq
- Market Cap
- FOXO 4.9M
- BGLC 5.8M
- IPO Year
- FOXO N/A
- BGLC N/A
- Fundamental
- Price
- FOXO $0.15
- BGLC $0.36
- Analyst Decision
- FOXO
- BGLC
- Analyst Count
- FOXO 0
- BGLC 0
- Target Price
- FOXO N/A
- BGLC N/A
- AVG Volume (30 Days)
- FOXO 5.9M
- BGLC 201.7K
- Earning Date
- FOXO 11-19-2024
- BGLC 03-25-2025
- Dividend Yield
- FOXO N/A
- BGLC N/A
- EPS Growth
- FOXO N/A
- BGLC N/A
- EPS
- FOXO N/A
- BGLC N/A
- Revenue
- FOXO $1,341,000.00
- BGLC $9,259,858.00
- Revenue This Year
- FOXO N/A
- BGLC N/A
- Revenue Next Year
- FOXO N/A
- BGLC N/A
- P/E Ratio
- FOXO N/A
- BGLC N/A
- Revenue Growth
- FOXO 196.03
- BGLC N/A
- 52 Week Low
- FOXO $0.13
- BGLC $0.21
- 52 Week High
- FOXO $1.30
- BGLC $1.00
- Technical
- Relative Strength Index (RSI)
- FOXO 35.01
- BGLC 51.88
- Support Level
- FOXO $0.14
- BGLC $0.30
- Resistance Level
- FOXO $0.17
- BGLC $0.41
- Average True Range (ATR)
- FOXO 0.02
- BGLC 0.03
- MACD
- FOXO 0.00
- BGLC 0.00
- Stochastic Oscillator
- FOXO 3.69
- BGLC 56.80
About FOXO FOXO Technologies Inc.
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.